BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32945624)

  • 1. Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.
    Lowe J; Kolkhof P; Haupt MJ; Peczkowski KK; Rastogi N; Hauck JS; Kadakia FK; Zins JG; Ciccone PC; Smart S; Sandner P; Raman SV; Janssen PML; Rafael-Fortney JA
    ESC Heart Fail; 2020 Dec; 7(6):3983-3995. PubMed ID: 32945624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise.
    Lowe J; Kadakia FK; Zins JG; Haupt M; Peczkowski KK; Rastogi N; Floyd KT; Gomez-Sanchez EP; Gomez-Sanchez CE; Elnakish MT; Rafael-Fortney JA; Janssen PML
    J Neuromuscul Dis; 2018; 5(3):295-306. PubMed ID: 30010143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
    Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
    J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.
    Chadwick JA; Bhattacharya S; Lowe J; Weisleder N; Rafael-Fortney JA
    Am J Physiol Cell Physiol; 2017 Feb; 312(2):C155-C168. PubMed ID: 27881412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy.
    Lowe J; Wodarcyk AJ; Floyd KT; Rastogi N; Schultz EJ; Swager SA; Chadwick JA; Tran T; Raman SV; Janssen PM; Rafael-Fortney JA
    J Neuromuscul Dis; 2015; 2(3):257-268. PubMed ID: 27110493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury.
    Howard ZM; Gomatam CK; Piepho AB; Rafael-Fortney JA
    Front Pharmacol; 2022; 13():942660. PubMed ID: 35837290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute AT
    Meyers TA; Heitzman JA; Krebsbach AM; Aufdembrink LM; Hughes R; Bartolomucci A; Townsend D
    J Mol Cell Cardiol; 2019 Mar; 128():51-61. PubMed ID: 30664850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.
    Crisp A; Yin H; Goyenvalle A; Betts C; Moulton HM; Seow Y; Babbs A; Merritt T; Saleh AF; Gait MJ; Stuckey DJ; Clarke K; Davies KE; Wood MJ
    Hum Mol Genet; 2011 Feb; 20(3):413-21. PubMed ID: 21062902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
    Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
    PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
    Rafael-Fortney JA; Chimanji NS; Schill KE; Martin CD; Murray JD; Ganguly R; Stangland JE; Tran T; Xu Y; Canan BD; Mays TA; Delfín DA; Janssen PM; Raman SV
    Circulation; 2011 Aug; 124(5):582-8. PubMed ID: 21768542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.
    Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW
    Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
    Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
    PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
    Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
    Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dystrophin-Deficient Cardiomyopathy.
    Kamdar F; Garry DJ
    J Am Coll Cardiol; 2016 May; 67(21):2533-46. PubMed ID: 27230049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.